Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) - OʼDonnell, P H (J Clin Oncol, 2017)
(suppl; abstr 4502); oral presentation (DOI: 10.1200/JCO.2017.35.15_suppl.4502, no. 15_suppl [May 2017])